ESMO: Gilead’s Trodelvy Outperforms Expectations In Breast Cancer, Again

 
• By Alaric DeArment
  
OS data from Gilead's TROPiCS-02 trial exceeded the expectations of many investors • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapy Areas